- Home
- JFU vs IGC Comparison
JFU vs IGC Comparison
Compare JFU & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFU | IGC |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 32.0M |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | JFU | IGC |
|---|---|---|
| Price | $2.85 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.0K | ★ 573.5K |
| Earning Date | 12-09-2022 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | $4,000.66 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $0.08 |
| 52 Week High | $9.48 | $0.45 |
Technical Indicators
Market Signals| Indicator | JFU | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 18.22 |
| Support Level | $2.20 | N/A |
| Resistance Level | $2.96 | $0.31 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 8.70 | 54.35 |
Price Performance
Historical ComparisonAbout JFU 9F Inc.
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.